CAR-T therapy developer Kite Pharma has licensed rights to a culturing system that replicates conditions in the thymus from researchers at the University of California.
Fresh from completing an off-the-shelf JHL plant and signing a $350m facility deal with Pfizer, GE believes modular bioprocessing could be the future.
Epirus Biopharmaceuticals has handed rights to its Remicade (infliximab) biosimilar to Reliance Life Sciences (RLS).
Janssen will keep production of its monoclonal antibody Remicade (infliximab) in-house despite encroaching biosimilar competition in the US.
Abzena will make Faron's drug candidate Clevegen - an antibody that neutralises a subset of immune cells linked to tumor proliferation - at a recently acquired single-use facility in California.
Bioprocess equipment vendors Pall and Sartorius have each cited demand for single-use technologies as a growth driver in the first half 2016.